A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo

Ki vehet részt

• Clinical diagnosis of nonsegmental vitiligo with genital involvement
• At least ≥ 0.25% BSA of nonsegmental vitiligo in the genital area
• Pigmented hair within some of the genital vitiligo areas
• At least 1 genital target lesion that is ≥ 0.1% BSA that has a pigmented hair within it
• Vitiligo on areas of the body besides the genitals
• Total body vitiligo area not exceeding 10% BSA
• Willing to have genital photography conducted
• Must agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted

Ki nem vehet részt

• Prior or current use of depigmentation treatments (eg, monobenzone)
• Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders
• An active sexually transmitted disease, sexually transmitted infection, or other skin disorder affecting the genital area (eg, scabies, fungal infection, molluscum)
• Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study or interpretation of study data
• Clinical laboratory test results outside of protocol defined ranges
• Active or recurrent genital warts or herpes
• Male participants with partners with known current/active cervical intraepithelial neoplasia or anal intraepithelial neoplasia
• Had ≥ 3 laser hair removal treatments in an area to be treated for vitiligo
• Pregnant or lactating participants, or those considering pregnancy during the period of their study participation